Canaccord analyst Richard Close raised the firm’s price target on LifeStance (LFST) to $9 from $8 and keeps a Buy rating on the shares. The firm updated its model to reflect opportunity amid an uncertain healthcare environment while the company could be insulated from much of the uncertainty in broader healthcare ecosystem, with payers continuing to be supportive of expanding in-network access to care.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST: